Autopsy report · NCT03831802

Embrace and Quality of Life

“because of technical issues”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 2 years 10 months before it stopped.
• 26 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Centre Hospitalier Universitaire Vaudois

Sponsor type

University, hospital or other

Conditions

Epilepsy, Tonic-Clonic

Interventions

Embrace with Alert and Mate apps; Embrace with Mate app only

Participants

26

Sites

1

Countries

Switzerland

Trials that died the same way

• Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
  “Due to business reasons” (77% match in meaning)
• Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors
  “Due to strategic reasons” (73% match in meaning)
• A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia
  “Due to administrative reasons” (71% match in meaning)
• Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML
  “Due to financial reasons.” (67% match in meaning)
• Clinical and Cost Effectiveness of Different Dressing Materials in Diabetic Foot Ulcers
  “Due to administrative reason” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.